您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > (±)-Lisofylline
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
(±)-Lisofylline
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
(±)-Lisofylline图片
CAS NO:6493-06-7
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍
(±)-Lisofylline ((±)-Lisophylline) 是 Lisofylline 的外消旋体。
Cas No.6493-06-7
别名利索茶碱,BL 194,CT-1501R,LSF
化学名3,7-dihydro-1-(5-hydroxyhexyl)-3,7-dimethyl-1H-purine-2,6-dione
Canonical SMILESCC(O)CCCCn1c(=O)c2n(C)cnc2n(C)c1=O
分子式C13H20N4O3
分子量280.3
溶解度≤2mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

(±)-Lisofylline is an anti-inflammatory agent.

Anti-inflammatory refers to the property of a agent or treatment reducing inflammation or swelling. Anti-inflammatory drugs make up about half of analgesics, remedying pain by reducing inflammation as opposed to opioids.

In vitro: (±)-Lisofylline is a potent anti-inflammatory agent in which only the (-) optical isomer is biologically active. (±)-Lisofylline was found to inhibit the generation of phosphatidic acid from cytokine-activated lysophosphatidic acyl transferase. (±)-Lisofylline could also suppress the production of the proinflammatory cytokine IFN-γ, inhibit IL-12-mediated STAT-4 activation, as well as enhance glucose-stimulated β-cell insulin secretion [1].

In vivo: In a previous study, lisofylline was administered to female non-obese diabetic mice for 3 weeks. Cytokines and blood glucose concentrations were monitored. Histology and immunohistochemistry were also carried out in pancreatic sections. Results showed that lisofylline was able to suppress IFN-γ production, reduce the onset of insulitis and diabetes, and inhibit diabetes [1].

Clinical trial: A clinical trial has been conducted to determine whether the administration of lisofylline would decrease mortality in patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). However, this trial was stopped for futility at the first scheduled interim analysis. It was found that there was no significant difference between groups in the number of patients who had died at 28 days and there was no significant difference between the lisofylline and placebo groups in terms of ventilator-free days, infection-related deaths, resolution of organ failures, or development of serious infection [2].

References:
[1] Yang, Z. D.,Chen, M.,Wu, R., et al. The anti-inflammatory compound lisofylline prevents type I diabetes in non-obese diabetic mice. Diabetologia 45, 1307-1314 (2002).
[2] No authors listed.  Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med. 2002 Jan;30(1):1-6.